Overcoming the Causes (and Consequences) of Chronic Hyperkalemia

To participate in this activity, please:

Chronic hyperkalemia has several possible causes, including impaired renal excretion of potassium due to a decrease in mineralocorticoid activity, often resulting from renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. While limiting potassium intake and avoiding the use of RAASi therapy are common strategies to manage patients who develop chronic hyperkalemia, both have important negative consequences on patient outcomes, particularly related to the kidneys. Sodium polystyrene sulfonate has often been used to bind potassium, but limited effectiveness and gastrointestinal toxicity limit its use. In the past few years, 2 additional potassium-binding agents have become available with evidence of effectiveness and safety. In addition, a nonsteroidal mineralocorticoid receptor antagonist with reduced potential for hyperkalemia has recently become available. This case-based activity touches on the diagnostic and clinical challenges faced in the primary care management of patients with chronic hyperkalemia with suggestions for integrating the evolving options into practice to improve patient outcomes. 

This program is also available as a podcast. You may download it here: https://anchor.fm/chronic-hyperkalemia

Course Credit:

1.00 AMA PRA Category 1 CreditTM

Dates:

Opens: 2022-02-09
Closes: 2023-02-09

Target Audience:

National audience of family medicine physicians and other healthcare professionals who work in the family medicine/primary care setting.

This activity is supported by an educational grant from AstraZeneca.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Biff F. Palmer, MD

    Professor of Internal Medicine
    UT Southwestern Medical Center
    Dallas, Texas

  • Contributing Faculty

    Robert Toto, MD

    Associate Dean, Clinical and Translational Research
    Director, Center for Translational Medicine
    UT Southwestern Medical Center
    Dallas, Texas

Learning Objectives

  • List common causes of hyperkalemia
  • Describe the clinical benefits of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in patients with chronic kidney disease and heart failure
  • Compare and contrast patiromer and sodium zirconium cyclosilicate for the treatment of chronic hyperkalemia, including safety and efficacy data
  • Identify opportunities to treat patients with potassium-binding agents, in accordance with the latest guidance, to help optimize the use of RAASi therapy

Faculty Disclosures

Biff F. Palmer, MD

No relationships to disclose.

Robert Toto, MD

Consultant:  Amgen, AstraZeneca, Boehringer Ingelheim, Chinook, Lilly, Novo Nordisk

Data Monitoring Committee:   Akebia, Otsuka, Reata